Using tiny particles to improve radiation treatment for a type of brain cancer in children
Official title: Harnessing Extracellular Vesicles to Overcome Radiation Resistance in Pediatric Diffuse Midline Glioma
Funded at University of Kentucky · NIH-10990146 · Data updated 2026-11-12
This study is looking at a type of brain tumor in kids that doesn't respond well to radiation treatment, and it's exploring how tiny particles released by the tumor might help us find better ways to make the radiation work more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $35,602 |
| NIH project number | 1F99CA294265-01 |
| Project ID | NIH-10990146 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 11 years old diagnosed with diffuse midline gliomas that have the H3K27M genetic alteration.
✕Less likely to help
Patients with other types of brain tumors or those over the age of 11 may not benefit from this research.
What this research studies
This research focuses on pediatric diffuse midline gliomas with a specific genetic alteration that makes them resistant to radiation therapy. The study aims to understand how extracellular vesicles, which are small particles released by tumor cells, contribute to this resistance and how they can be used to deliver new treatments that enhance the effectiveness of radiation. By investigating the role of these vesicles and their contents, particularly microRNAs, the research seeks to develop innovative strategies to sensitize these tumors to existing therapies. This approach combines engineering and cancer biology to potentially improve outcomes for affected children.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for a deadly form of pediatric brain cancer, improving survival rates and quality of life for young patients.
How similar studies have gone: While the use of extracellular vesicles in cancer treatment is a growing field, this specific approach targeting radiation resistance in pediatric gliomas is novel and has not been extensively tested.
Where this research is happening
-
University of Kentucky
Lexington, United States Active
Researchers
- Principal investigator: Oza, Viral — University of Kentucky
- Study coordinator: Oza, Viral
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.